시장보고서

상품코드

1606456

2형 당뇨병 시장 : 약물 등급별, 투여 경로별, 유통 채널별, 최종 사용자별, 국가별, 지역별-산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Type 2 Diabetes Market, By Drug Class, By Route of Administration, By Distribution Channel, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 11월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 288 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

2형 당뇨병 시장 규모는 2023년 348억 4,909만 달러로 평가되었고, 2024년부터 2032년까지 연평균 복합 성장률(CAGR) 8.40%로 확대될 전망입니다

2형 당뇨병 시장-시장 역학

세계의 2형 당뇨병 이환율 증가로 시장 수요 촉진

세계에서 2형 당뇨병의 이환율이 상승하고 있는 것은 주로 라이프스타일의 변화와 인구의 고령화가 원인이며, 이것이 2형 당뇨병 시장의 성장을 가속하는 주요 요인이 되고 있습니다. 세계 보건기구(WHO)에 따르면, 당뇨병 환자의 95% 이상이 2형 당뇨병입니다. 또한 세계의 비만과 과체중 증가는 2형 당뇨병의 이환율의 상승과 밀접한 관계가 있으며, 과잉 체중은 인슐린 저항성을 현저하게 증가시키기 때문입니다. 그러나 당뇨병 치료 기기는 고가이며, 의약품의 진보에도 불구하고 많은 환자들이 새로운 당뇨병 치료제의 존재를 모르기 때문에 당뇨병 치료 기기의 보급이 제한되어 시장 성장이 둔화되고 있습니다. 글루카곤 유사 펩타이드-1수용체 작용제(Tanzeum, Trulicity) 및 나트륨 글루코스 공수송체-2 억제제(Jardiance)와 같은 의약품 개발은 2형 당뇨병 시장에 큰 성장 기회를 가져올 것으로 예측됩니다.

2형 당뇨병 시장-주요 인사이트

우리의 리서치 애널리스트가 공유한 분석에 따르면 세계 시장은 예측 기간(2024-2032년)에 약 8.40%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 예측됩니다.

약물 등급별로, 나트륨 글루코스 공수송체 2(SGLT2) 억제제는 2023년 최대 시장 점유율을 나타낸 것으로 평가됩니다.

투여 경로별로, 경구제는 2023년에 주요 부문이었습니다.

최종 사용자별로 2023년에는 재택 간호가 주요 부문이었습니다.

지역별로는 북미의 2형 당뇨병 시장이 2023년 주요 수익원이었습니다.

2형 당뇨병 시장-세분화 분석 :

세계의 2형 당뇨병 시장은 약물 클래스별, 투여 경로별, 유통 채널별, 최종 사용자별, 지역별로 구분됩니다.

약물 등급별로는 디펩티딜 펩티다아제 4 억제제, 나트륨 글루코스 공수송체 2(SGLT2) 억제제, 글루카곤-유사 펩티드 1 수용체 작용제, 기타 4가지로 분류됩니다. 시장을 독점하고 있는 것은 나트륨 글루코오스 공수송체2(SGLT2) 억제제입니다. 이것은 주로, 혈당치를 내리고, 심혈관 이벤트나 신장 이벤트의 리스크를 저감하는 효과에 의한 것입니다.

시장은 유통 채널별로 온라인 약국, 소매 약국, 병원 약국의 3가지로 분류됩니다. 예측 기간 동안 온라인 부문이 가장 높은 CAGR로 상승할 것으로 예측됩니다. 이는 주로 당뇨병 치료제에 대한 편리한 접근에 대한 수요가 증가함에 따라 환자가 집에서 쉽게 처방전을 주문할 수 있게 되어 많은 환자에게 좋은 선택지가 되고 있기 때문입니다.

2형 당뇨병 시장-지리적 인사이트

지리적으로, 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카의 각 지역으로 퍼져 있습니다. 이러한 지역은 비즈니스를 선도하는 국가에 따라 더 나뉩니다.

2형 당뇨병 시장-경쟁 구도 :

세계의 2형 당뇨병 시장은 이 질환의 유병률 증가와 효과적인 관리 옵션에 대한 수요 증가에 따라 급속히 성장하고 있습니다. 이 시장의 경쟁 구도는, 전자상거래나 소매점과의 제휴 등 여러가지 유통 채널을 활용하는 국내외의 기업에 의해서 구성되어 있습니다. 각사는 경쟁력 있는 가격 설정, 제품의 품질, 기술 혁신에 의해서 차별화를 도모하고 있습니다. 시장 점유율을 확대하기 위한 주요 전략에는 신제품 출시, 연구개발 투자, M&A 추진 등이 있으며, 이들은 모두 효과적인 당뇨병 치료를 요구하는 환자의 진화하는 요구에 부응하는 것을 목적으로 하고 있습니다.

서문
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 : 2형 당뇨병 업계

경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
기업 프로파일
- Eli Lilly and Company
- Sanofi
- Merck &Co., Inc.
- AstraZeneca PLC
- Boehringer Ingelheim
- GlaxoSmithKline plc
- Pfizer Inc.
- Novartis AG
- Roche Holding AG
- Daiichi Sankyo Company, Limited
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy's Laboratories Ltd.
- Aurobindo Pharma Limited
- Lupin Limited
- Medtronic
- B. Braun Melsungen AG
- F. Hoffmann-La Roche
- Abbott Laboratories
- Insulet Corporation
- Torrent Pharmaceuticals Limited
- Takeda Pharmaceuticals Limited
- Acon Laboratories, Inc.
- Akros Pharma
- Adocia
- Amgen
- Bayer AG
- Biocon
- Becton, Dickson, and Company
- Peptron
- Others

제13장 애널리스트의 전방위 전망

AJY 24.12.27

REPORT HIGHLIGHT

Type 2 diabetes market size was valued at USD 34,849.09 Million in 2023, expanding at a CAGR of 8.40% from 2024 to 2032.

Type 2 diabetes is a chronic metabolic disorder where the body either resists insulin or doesn't produce enough of it, leading to high blood sugar levels. Symptoms may be mild or unnoticed for years, with signs like increased thirst, frequent urination, fatigue, or tingling in the hands and feet. Diagnosis typically involves blood tests like fasting plasma glucose or the A1C test to assess average blood sugar levels.

Type 2 Diabetes Market- Market Dynamics

Increasing prevalence of type 2 diabetes across the globe to propel market demand

The rising incidence of type 2 diabetes among people worldwide is mainly due to the lifestyle changes and aging populations is the major factor driving the growth of the type 2 diabetes market. According to the World Health Organization (WHO), more than 95% of people with diabetes have type 2 diabetes. Besides, the global rise in obesity and overweight individuals is closely linked to higher rates of type 2 diabetes, as excess weight significantly increases insulin resistance. However high cost of devices and despite pharmaceutical advancements, many patients are unaware of novel diabetes drugs, limiting their adoption and slowing market growth. On the contrary, pharmaceutical developments, such as glucagon-like peptide-1 receptor agonists (Tanzeum, Trulicity) and sodium glucose cotransporter-2 inhibitors (Jardiance) are predicted to create massive growth opportunities for the type 2 diabetes market.

Type 2 Diabetes Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.40% over the forecast period (2024-2032)

Based on drug class segmentation, sodium-glucose cotransporter 2 (SGLT2) inhibitors was predicted to show maximum market share in the year 2023

Based on route of administration segmentation, oral was the leading segment in 2023

Based on end-user segmentation, homecare was the leading segment in 2023

On the basis of region, the North America type 2 diabetes market was the leading revenue generator in 2023

Type 2 Diabetes Market- Segmentation Analysis:

The Global Type 2 Diabetes Market is segmented on the basis of Drug Class, Route of Administration, Distribution Channel, End User, and Region.

The market is divided into four categories based on drug class: dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 receptor agonists, and others. The sodium-glucose cotransporter 2 (SGLT2) sector dominates the market. This is majorly owing to their effectiveness in lowering blood sugar and reducing the risk of cardiovascular and renal events.

The market is divided into three categories based on distribution channel: online pharmacies, retail pharmacies, and hospital pharmacies. The online sector is predicted to rise at the highest CAGR during the forecast period. This is mainly because the increasing demand for convenient access to diabetes medications allows patients to order prescriptions easily from home, making it a preferred option for many.

Type 2 Diabetes Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Type 2 Diabetes Market- Competitive Landscape:

The global type 2 diabetes market is rapidly growing, driven by the increasing prevalence of the disease and rising demand for effective management options. This market features a competitive landscape comprised of both international and local players who utilize various distribution channels, including e-commerce and retail partnerships. Companies differentiate themselves through competitive pricing, product quality, and innovation. Key strategies for expanding market share include launching new products, investing in research and development, and pursuing mergers and acquisitions, all aimed at meeting the evolving needs of patients seeking effective diabetes care.

Recent Developments:

In October 2023, Glenmark Pharmaceuticals announced the launch of India's first triple-drug fixed-dose combination (FDC) therapy for adults with Type 2 diabetes and comorbidities. Named Zita DM, the drug combines three medications to enhance glycemic control, helping patients maintain optimal blood glucose levels. This marks a significant innovation in diabetes management in India.

In June 2024, the FDA approved AstraZeneca's Farxiga (dapagliflozin) to help control blood sugar levels in children aged 10 and up with type 2 diabetes. This approval is based on encouraging findings from the T2NOW Phase III trial. Farxiga was previously authorized for adults, supporting blood sugar management alongside diet and exercise.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL TYPE 2 DIABETES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Novo Nordisk
Eli Lilly and Company
Sanofi
Merck & Co., Inc.
AstraZeneca PLC
Boehringer Ingelheim
GlaxoSmithKline plc
Pfizer Inc.
Novartis AG
Roche Holding AG
Daiichi Sankyo Company, Limited
Sun Pharmaceutical Industries Ltd.
Dr. Reddy's Laboratories Ltd.
Aurobindo Pharma Limited
Lupin Limited
Medtronic
B. Braun Melsungen AG
F. Hoffmann-La Roche
Abbott Laboratories
Insulet Corporation
Torrent Pharmaceuticals Limited
Takeda Pharmaceuticals Limited
Acon Laboratories, Inc.
Akros Pharma
Adocia
Amgen
Bayer AG
Biocon
Becton, Dickson, and Company
Peptron
Others

GLOBAL TYPE 2 DIABETES MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

Dipeptidyl Peptidase-4 Inhibitors
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Glucagon-like Peptide 1 Receptor Agonists
Others

GLOBAL TYPE 2 DIABETES MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Parenteral
Oral

GLOBAL TYPE 2 DIABETES MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Online Pharmacies
Retail Pharmacies
Hospital Pharmacies

GLOBAL TYPE 2 DIABETES MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Hospitals & Clinics
Homecare Settings
Academic & Research Institutes
Others

GLOBAL TYPE 2 DIABETES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Type 2 Diabetes Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Type 2 Diabetes Market Snippet by Drug Class
- 2.1.2. Type 2 Diabetes Market Snippet by Route of Administration
- 2.1.3. Type 2 Diabetes Market Snippet by Distribution Channel
- 2.1.4. Type 2 Diabetes Market Snippet by End User
- 2.1.5. Type 2 Diabetes Market Snippet by Country
- 2.1.6. Type 2 Diabetes Market Snippet by Region
2.2. Competitive Insights

3. Type 2 Diabetes Key Market Trends

3.1. Type 2 Diabetes Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Type 2 Diabetes Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Type 2 Diabetes Market Opportunities
3.4. Type 2 Diabetes Market Future Trends

4. Type 2 Diabetes Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Type 2 Diabetes Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Type 2 Diabetes Market Landscape

6.1. Type 2 Diabetes Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Type 2 Diabetes Market - By Drug Class

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
- 7.1.2. Dipeptidyl Peptidase-4 Inhibitors
- 7.1.3. Sodium-glucose Cotransporter (SGLT2) Inhibitors
- 7.1.4. Glucagon-like Peptide 1 Receptor Agonists
- 7.1.5. Others

8. Type 2 Diabetes Market - By Route of Administration

8.1. Overview
- 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 8.1.2. Parenteral
- 8.1.3. Oral

9. Type 2 Diabetes Market - By Distribution Channel

9.1. Overview
- 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
- 9.1.2. Online Pharmacies
- 9.1.3. Retail Pharmacies
- 9.1.4. Hospital Pharmacies

10. Type 2 Diabetes Market - By End User

10.1. Overview
- 10.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
- 10.1.2. Hospitals & Clinics
- 10.1.3. Homecare Settings
- 10.1.4. Academic & Research Institutes
- 10.1.5. Others

11. Type 2 Diabetes Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Type 2 Diabetes Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Type 2 Diabetes Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.9. Italy
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.9.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.9.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.3.9.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.10. United Kingdom
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.10.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.10.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.11. France
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.11.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.11.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.3.11.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.12. Russia
  - 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.12.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.13. Netherlands
  - 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.13.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.13.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.15. Poland
  - 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.15.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.16. Rest of Europe
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Type 2 Diabetes Key Manufacturers in Asia Pacific
- 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.8. India
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.8.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.8.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.4.8.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.9. China
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.9.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.9.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.4.9.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.13. Thailand
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.14. Indonesia
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5. Latin America
- 11.5.1. Overview
- 11.5.2. Type 2 Diabetes Key Manufacturers in Latin America
- 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
- 11.6.1. Overview
- 11.6.2. Type 2 Diabetes Key Manufacturers in Middle East and Africa
- 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Type 2 Diabetes Industry

12.1. Competitive Dashboard
- 12.1.1. Competitive Benchmarking
- 12.1.2. Competitive Positioning
12.2. Company Profiles
- 12.2.1. Eli Lilly and Company
- 12.2.2. Sanofi
- 12.2.3. Merck & Co., Inc.
- 12.2.4. AstraZeneca PLC
- 12.2.5. Boehringer Ingelheim
- 12.2.6. GlaxoSmithKline plc
- 12.2.7. Pfizer Inc.
- 12.2.8. Novartis AG
- 12.2.9. Roche Holding AG
- 12.2.10. Daiichi Sankyo Company, Limited
- 12.2.11. Sun Pharmaceutical Industries Ltd.
- 12.2.12. Dr. Reddy's Laboratories Ltd.
- 12.2.13. Aurobindo Pharma Limited
- 12.2.14. Lupin Limited
- 12.2.15. Medtronic
- 12.2.16. B. Braun Melsungen AG
- 12.2.17. F. Hoffmann-La Roche
- 12.2.18. Abbott Laboratories
- 12.2.19. Insulet Corporation
- 12.2.20. Torrent Pharmaceuticals Limited
- 12.2.21. Takeda Pharmaceuticals Limited
- 12.2.22. Acon Laboratories, Inc.
- 12.2.23. Akros Pharma
- 12.2.24. Adocia
- 12.2.25. Amgen
- 12.2.26. Bayer AG
- 12.2.27. Biocon
- 12.2.28. Becton, Dickson, and Company
- 12.2.29. Peptron
- 12.2.30. Others

13. 360 Degree Analyst View

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us